GB1048104A - Pharmaceutical compositions containing 3,5-disubstituted pyrazoles - Google Patents

Pharmaceutical compositions containing 3,5-disubstituted pyrazoles

Info

Publication number
GB1048104A
GB1048104A GB5292/64A GB529264A GB1048104A GB 1048104 A GB1048104 A GB 1048104A GB 5292/64 A GB5292/64 A GB 5292/64A GB 529264 A GB529264 A GB 529264A GB 1048104 A GB1048104 A GB 1048104A
Authority
GB
United Kingdom
Prior art keywords
sodium
acid
ethyl
alkyl
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5292/64A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB1048104A publication Critical patent/GB1048104A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

3,5-Disubstituted pyrazoles of formula <FORM:1048104/C2/1> wherein R1 is alkyl and R2 is carboxyl, carbamoyl, alkoxycarbonyl, or alkyl monosubstituted carbamoyl, alkyl being C1 to C4, are prepared by reacting together hydrazine and an appropriate keto-acid; (i.e. a pyruvic or substituted pyruvic acid). The following examples illustrate this procedure: (1) Acetopyruvic acid and hydrazine sulphate are reacted in aqueous solution at 50 DEG C. to yield 3-carboxy-5-methyl pyrazole, which is purified by recrystallization from isopropanol-ethanol; (3) sodium ethylpropiopyruvate and hydrazine sulphate are reacted in aqueous sodium acetate solution at below 30 DEG C. to yield 3-ethoxycarbonyl-5-ethyl pyrazole. The latter is used to prepare 3-carboxy-5-ethyl -pyrazole, by further reaction with sodium hydroxide; (4) the product of Example 1 is converted to its sodium salt with sodium carbonate; also the following are said to be similarly obtainable: salts of K, Al, Ca, Mg, NH4, and procaine, N,N1-dibenzylethylenediamine, and diethanolamine; (5) sodium ethyl acetopyruvate and hydrazine sulphate are reacted in aqueous sodium acetate solution at 45 DEG C. to yield 3-ethoxycarbonyl-5-methylpyrazole; (6) the product of the latter example is used to prepare 3-carbamoyl-5-methyl pyrazole by further reaction with ammonium hydroxide at elevated temperature; (7) the product of Example (1) is dimerized by heating in thionyl chloride, and the dimer heated with 40% aqueous methylamine whereupon 3-Nmethylcarbamoyl - 5 - methyl pyrazole is produced. The preparation of the aforesaid substituted pyruvic acids is also illustrated in the following examples: (3) methyl ethyl ketone and sodium ethoxide, in ethanolic solution, are reacted at 15 DEG C., to yield sodium ethyl-propiopyruvate; (5) ethyl oxalate and acetone are refluxed with sodium ethoxide in ethanol to yield sodium ethyl acetopyruvate. The substituted pyrazoles are of use in pharmaceutical compositions (see Division A5).ALSO:Hypoglycemic compositions comprise a 3, 5-disubstituted pyrazole of formula <FORM:1048104/A5-A6/1> wherein R1 is alkyl, and R2 is carboxyl, alkoxycarbonyl, carbamoyl, or alkyl monosubstituted carbamoyl, alkyl being C1 to C4, or physiologically acceptable salts thereof, dispersed in a solid vehicle or in a liquid which is a non-solvent for the active ingredient. The compositions may be in unit dosage forms for oral or parenteral administration, such as tablets, pills, capsules, powders, wafers, cachets, granules, oral or sterile parenteral aqueous or non-aqueous dispersions including elixirs, or suppositories. Tablets and pills may be laminated to provide prolonged, delayed, or successive action; enteric coating materials employed may be shellac, shellac with cetyl alcohol, cellulose acetate phthalate, polymeric acids and particularly a styrenemaleic acid copolymer. Other optional ingredients of the compositions include conventional suspending and dispersing agents, solid excipients, surface active agents, preservatives, salts to effect isotonicity, oils, synthetic sweeteners, flavouring agents, dyes and other non-sugar containing ingredients. The compositions may further contain other active ingredients, such as other hypoglycemics, e.g. tolbutamide, chlorpropamide, phenformin HCl, mesoxalic acid, insulin, or nicotinic acid; utilizable potassium salts; hypocholesteremic agents; e.g. D-3, 5, 31-triiodothyronine, triiodothyropropionic acid, sodium L-or sodium D-thyroxine; glucocortiocoids, e.g. hydrocortisone, prednisolone, and 6a -methyl prednisolone; anticoagulants, e.g. heparin, 2-diphenyl acetyl-1, 3-indandione, polethylene sulphonate, and dicoumarol; vitamins, e.g. nicotinic acid, vitamin B12, ascorbic acid, or pyridoxine HCl; estrogens, e.g. estradiol; and androgens, e.g. testosterone; antibiotics, e.g. neomycin; analgesics such as aspirin; cholesterol metabolites such as a -phenyl-and a -p-biphenyl-butyric acid; lipotropic agents, e.g. choline and inositol; amino acids, e.g. taurine and glycine; plant sterols such as sitosterol; diuretics, such as ethoxazolamide or hydrochlorthiazide; anorectics such as amphetamine; and cardiovascular agents such as chlorisondamine chloride, hexamethonium chloride and pentaerythrital tetranitrate. Also mentioned are salts of the essential ingredient with a physiologically active base-i.e. diethanolamine, N,N1-dibenzylethylenediamine, or procaine. Examples include compositions for oral and parenteral use, and synthetic processes for preparing the inventive active ingredients, (see Division C2)
GB5292/64A 1963-03-04 1964-02-07 Pharmaceutical compositions containing 3,5-disubstituted pyrazoles Expired GB1048104A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26236663A 1963-03-04 1963-03-04

Publications (1)

Publication Number Publication Date
GB1048104A true GB1048104A (en) 1966-11-09

Family

ID=22997187

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5292/64A Expired GB1048104A (en) 1963-03-04 1964-02-07 Pharmaceutical compositions containing 3,5-disubstituted pyrazoles

Country Status (4)

Country Link
BE (1) BE644691A (en)
FR (1) FR3259M (en)
GB (1) GB1048104A (en)
NL (1) NL6402170A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029363A1 (en) * 1979-11-16 1981-05-27 Morishita Pharmaceutical Co. Ltd. Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0029364A1 (en) * 1979-11-16 1981-05-27 Morishita Pharmaceutical Co. Ltd. 5-Alkylpyrazol-3-carboxylic acid derivatives for use in therapy
WO2004032928A1 (en) * 2002-10-10 2004-04-22 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
CN117924265A (en) * 2024-03-22 2024-04-26 潍坊新绿化工有限公司 Synthesis method of pyrifos

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0029363A1 (en) * 1979-11-16 1981-05-27 Morishita Pharmaceutical Co. Ltd. Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0029364A1 (en) * 1979-11-16 1981-05-27 Morishita Pharmaceutical Co. Ltd. 5-Alkylpyrazol-3-carboxylic acid derivatives for use in therapy
US4323576A (en) * 1979-11-16 1982-04-06 Morishita Pharmaceutical Co., Ltd. Derivatives of pyrazole for use in therapy
WO2004032928A1 (en) * 2002-10-10 2004-04-22 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
CN117924265A (en) * 2024-03-22 2024-04-26 潍坊新绿化工有限公司 Synthesis method of pyrifos

Also Published As

Publication number Publication date
FR3259M (en) 1965-04-20
NL6402170A (en) 1964-09-07
BE644691A (en) 1964-09-04

Similar Documents

Publication Publication Date Title
US3755349A (en) Alpha-substituted benzyl-imidazoles
US3097210A (en) Substituted pyrazole sulfonamides
GB808105A (en) New pharmaceutical compositions
PL95259B1 (en) THE METHOD OF MAKING NEW DOUGUANID SALTS
GB1048104A (en) Pharmaceutical compositions containing 3,5-disubstituted pyrazoles
GB1495733A (en) Pharmaceutical preparations
ES345981A1 (en) Pyridines and poultry feedstuffs and additives thereof containing pyridines
US2868802A (en) Nxchj
IE45624L (en) (pyrazol-1-yl)-phenylacetic acids.
GB1411583A (en) Aminophenyl-substituted alkyl-heterocyclic derivatives and processes for producing them
GB968460A (en) Novel hydrazine derivatives and a process for the manufacture thereof
IL43079A (en) 2-amino-1,4-dihydropyridines,their production and pharmaceutical compositions containing them
US3072720A (en) Novel n-arylsulfonyl-n&#39;-(2, 5-endomethylene-1, 2, 5, 6-tetrahydrobenzyl) ureas
ES8307224A1 (en) Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them.
IL30350A (en) Benzodiazepine derivatives and process for the manufacture thereof
JPS57209223A (en) Microcapsule for intracranial anti hypotension and its production
IL34203A (en) Aryl-sulphonyl-ureas and aryl-sulphonyl-semicarbazides containing a (heterocyclic acyl)-amino group
US3991186A (en) Steryl-β-D-glucoside ester pharmaceutical compositions and method of use
US3551436A (en) Certain 4-(thiazolyl) and 4-(oxazolyl) pyridinium salts
US2983750A (en) Tris methylammonium salicylate salts
PL103692B1 (en) METHOD OF MAKING BENZENESULPHONYL UREAS
IE32706B1 (en) Novel alpha-carboline derivatives,the preparation thereof and compositions containing the same
DE1905881A1 (en) Process for the preparation of new heterocyclic compounds
GB1109690A (en) 5-oxo-3,4,5,6-tetrahydro-1h-azepino[4,3,2-cd]indoles and the manufacture thereof
GB1113262A (en) Improvements in or relating to substituted pyrazines and the manufacture thereof